news UTX gene mutation “robs” individuals of natural cancer protection 10 November 2021 | By Anna Begley (Drug Target Review) The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
news Researchers identify RNA molecule that suppresses prostate tumours 8 November 2021 | By Anna Begley (Drug Target Review) Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
news New class of CAR T cells combat previously “untargetable” cancer drivers 4 November 2021 | By Anna Begley (Drug Target Review) The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
news Experimental drug boosts immunotherapy efficacy for pancreatic cancer 4 November 2021 | By Anna Begley (Drug Target Review) An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
news Albert Einstein researcher receives NIC award to study two blood cancers 28 October 2021 | By Anna Begley (Drug Target Review) Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
news Raman spectroscopy used to determine immunotherapy effectiveness 28 October 2021 | By Anna Begley (Drug Target Review) Researchers used Raman spectroscopy to monitor immunotherapy response in mice, potentially improving cancer treatments in the future.
video Engineering better CAR T cells with Professor Ann Ager, Cardiff University 27 October 2021 | By Drug Target Review Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
news Molecular targets for breast cancer relapse identified in new study 26 October 2021 | By Anna Begley (Drug Target Review) German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
news Targeting channel in cell lysosome could selectively kill cancer cells 25 October 2021 | By Anna Begley (Drug Target Review) Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
news Nanofibre platform shows potential for inhibiting brain tumour growth 22 October 2021 | By Anna Begley (Drug Target Review) Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
news $7.5 million to fund senescent cell research for age-related disease 22 October 2021 | By Anna Begley (Drug Target Review) Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
news Algorithm identifies cancer drugs to treat pulmonary hypertension 21 October 2021 | By Anna Begley (Drug Target Review) Scientists have identified potential cancer drugs to treat pulmonary hypertension using experimental and computational approaches.
news MIT study reveals how lipid imbalance affects cancer growth in mice 21 October 2021 | By Anna Begley (Drug Target Review) In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
news Medicenna’s MDNA11 a promising alternative to checkpoint inhibitors 19 October 2021 | By Anna Begley (Drug Target Review) Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
news Scientists uncover answer to colorectal cancer immunotherapy resistance 13 October 2021 | By Anna Begley (Drug Target Review) Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.